Related Experiment Video
Updated: Jun 16, 2025
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
[Progress of IL-21 and Tfh Mediated Immunotherapy in Non-small Cell Lung Cancer]
Xingkai Liu1,2, Yifan Zhang1,2, Xin Zhang3
1Department of Cardiothoracic Surgery, 920th Hospital of Joint Logistic Support Force of the People's Liberation Army, Kunming 650032, China.
Abstract:
Non-small cell lung cancer (NSCLC) is a prevalent and aggressive global malignancy. Conventional surgical treatments, radiotherapy, chemotherapy, and targeted therapies often fall short in halting disease progression due to inherent limitations, resulting in suboptimal prognosis. Despite the advent of immunotherapy drugs offering new hope for NSCLC treatment, current efficacy remains insufficient to meet all patient needs. Therefore, actively exploring novel immunotherapeutic approaches to further reduce mortality rates in NSCLC patients has become a crucial focus of NSCLC research. This article aims to systematically review the anti-tumor effects of interleukin-21 and follicular helper T cells in NSCLC immunotherapy by summarizing and analyzing relevant literatures from both domestic and international sources, as well as exploring the potential for enhancing NSCLC treatment prospects through immune checkpoint regulation via immunotherapeutic means. .
Insights
Novel immunotherapies targeting interleukin-21 and follicular helper T cells show promise for improving outcomes in non-small cell lung cancer (NSCLC). Further research into immune checkpoint regulation could enhance treatment efficacy for NSCLC patients.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Non-small cell lung cancer (NSCLC) presents a significant global health challenge with limited success of conventional treatments.
- Current immunotherapies offer hope but have insufficient efficacy for many NSCLC patients.
- There is a critical need for novel immunotherapeutic strategies to improve NSCLC patient prognosis.
Purpose of the Study:
- To systematically review the anti-tumor effects of interleukin-21 (IL-21) in NSCLC immunotherapy.
- To analyze the role of follicular helper T cells (Tfh) in NSCLC immune responses.
- To explore immune checkpoint regulation as a strategy to enhance NSCLC immunotherapy.
Main Methods:
- Systematic literature review of domestic and international research.
- Analysis of anti-tumor mechanisms of IL-21 and Tfh cells in NSCLC.
- Investigation of immunotherapeutic approaches involving immune checkpoint modulation.
Main Results:
- Interleukin-21 demonstrates significant anti-tumor activity in preclinical and clinical NSCLC models.
- Follicular helper T cells play a crucial role in orchestrating anti-tumor immunity within the NSCLC microenvironment.
- Immune checkpoint inhibitors combined with IL-21 or Tfh cell modulation show synergistic potential.
Conclusions:
- Interleukin-21 and follicular helper T cells represent promising targets for novel NSCLC immunotherapies.
- Modulating immune checkpoints alongside IL-21 or Tfh cell-based strategies may overcome current treatment limitations.
- Further research is warranted to translate these findings into improved clinical outcomes for NSCLC patients.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...